Genmab AS - Company Profile
Powered by 
All the data and insights you need on Genmab AS in one report.
$295
- Save hours of research time and resources with
our up-to-date Genmab AS Strategy Report
- Understand Genmab AS position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
View up-to-date information on Genmab AS patents, including inventor and filing insights.
Patent Trends
| Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
|---|---|---|---|---|
| EP4055046A1 | Application | ANTIKÖRPERVARIANTENKOMBINATIONEN UND VERWENDUNGEN DAVON | A61K2039/505; A61K2039/507; A61P29/00; A61P31/00; A61P35/00; A61P37/06; C07K16/2878; C07K16/2887; C07K16/2893; C07K16/2896; C07K2317/41; C07K2317/524; C07K2317/526; C07K2317/71; C07K2317/734 | September 14, 2022 |
| CN114989302A | Application | 人源化或嵌合CD3抗体 | A61K2039/505; A61P31/00; A61P35/00; A61P37/02; C07K16/2809; C07K16/32; C07K16/4216; C07K2317/24; C07K2317/31; C07K2317/526; C07K2317/55; C07K2317/565; C07K2317/73; C07K2317/92 | September 02, 2022 |
| US20220273809A1 | Application | AXL ANTIBODY-DRUG CONJUGATES FOR USE IN TREATING CANCER | A61K2121/00; A61K47/02; A61K47/6803; A61K47/6843; A61P35/00 | September 01, 2022 |
| CN114980927A | Application | CD38抗体的配制剂及其用途 | A61K2039/505; A61K39/3955; C07K16/18; C07K16/2896; C07K16/40; C07K2317/24; C07K2317/33; C07K2317/73; C07K2317/732; C07K2317/734; C07K2317/76; C07K2317/92 | August 30, 2022 |
| US20220265844A1 | Application | DOSING REGIMENS FOR ANTI-TF-ANTIBODY DRUG-CONJUGATES | A61K38/07; A61K47/6803; A61K47/6811; A61K47/6843; C07K16/36 | August 25, 2022 |
Top Inventors by Filings (Count by publication)
| Name | Count |
|---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer